Povorcitinib在第三阶段试验中显著改善了隐藏性肝炎症状,60%的患者的症状至少减少了50%。 Povorcitinib significantly improved hidradenitis suppurativa symptoms in a Phase 3 trial, with 60% of patients seeing at least 50% symptom reduction.

在2025年欧洲皮肤病学和阴道病学学会上,Incyte展示了STOP- HS试验的24周第三期数据,显示口服JAK1抑制剂povorcitinib显著改善了中度至重度上腺炎 (HS) 的成年人症状. At the 2025 European Academy of Dermatology and Venereology Congress, Incyte presented 24-week Phase 3 data from the STOP-HS trials showing that povorcitinib, an oral JAK1 inhibitor, significantly improved symptoms in adults with moderate to severe hidradenitis suppurativa (HS). 该药物导致在临床上有意义和持续地减少皮肤疼痛、疾病严重程度和突发事件,大约60%的病人到第24周症状有50%的改善。 The drug led to clinically meaningful and sustained reductions in skin pain, disease severity, and flare-ups, with about 60% of patients achieving a 50% improvement in symptoms by week 24. 各关键端点的结果一致,安全情况保持稳定。 Results were consistent across key endpoints, and the safety profile remained stable. 这些数据支持了欧洲和美国即将提交的关于这种可能的新治疗的监管文件。 The data supports upcoming regulatory submissions in Europe and the U.S. for this potential new treatment.